文献速递血栓与止血

血小板因子4增强血小板活化试验诊断肝素诱导血小板减少症的比较研究

A comparative study of platelet factor 4-enhanced platelet activation assays for the diagnosis of heparin-induced thrombocytopenia.
PubMed 文献 · J Thromb Haemost · 2021-02-19

该研究在单一参考实验室比较了三种PF4增强血小板活化试验(PF4/肝素-SRA、PF4-SRA和P-选择素表达试验PEA)的诊断性能。转诊队列(n=84)中三种试验均检出所有SRA阳性样本,特异性分别为PF4/肝素-SRA 96.6%、PF4-SRA 84.7%、PEA 67.8%。临床队列(n=101)中SRA类试验性能均高(敏感性>92.1%,特异性>98.4%),PEA敏感性65.8%、特异性63.5%,预选血小板供者后提高至92.1%和96.8%。

要点

  • 三种PF4增强试验在预选血小板供者时均显示良好诊断性能。
  • 转诊队列中PF4/肝素-SRA特异性最高(96.6%),PEA最低(67.8%)。
  • PEA性能依赖供者选择,预选后敏感性92.1%、特异性96.8%。

核心结论

  • 所有PF4增强试验在预选血小板供者时均表现出良好的诊断性能。
  • 需多实验室进一步比较以就HIT最佳诊断检测达成共识。

研究设计与样本

  • 单中心参考实验室比较三种PF4增强血小板活化试验。
  • 转诊队列n=84,为既往HIT诊断检测且SRA阳性或阴性的样本。
  • 临床队列n=101,为临床确诊HIT且血清含血小板活化抗体的样本。

主要发现

  • 转诊队列中三种PF4增强试验均检出所有SRA阳性样本。
  • 转诊队列特异性:PF4/肝素-SRA 96.6%,PF4-SRA 84.7%,PEA 67.8%。
  • 临床队列SRA类试验敏感性>92.1%、特异性>98.4%。
  • 临床队列PEA敏感性65.8%、特异性63.5%。
  • 预选血小板供者后PEA敏感性92.1%、特异性96.8%。

关键数值与推荐

  • 转诊队列特异性:PF4/肝素-SRA 96.6%,PF4-SRA 84.7%,PEA 67.8%。
  • 临床队列SRA类试验敏感性>92.1%、特异性>98.4%。
  • 临床队列PEA敏感性65.8%、特异性63.5%,预选供者后为92.1%和96.8%。

临床怎么用

  • PF4增强血小板活化试验可用于HIT诊断,预选血小板供者可优化PEA性能。

局限性

  • 研究在单一参考实验室进行,结论外推需多实验室验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Functional platelet activation assays, such as the serotonin release assay (SRA), are the gold standard for the diagnosis of heparin-induced thrombocytopenia (HIT). Recently, platelet activation assays using added platelet factor 4 (PF4) have been described and suggest improved sensitivity. Direct comparisons of these assays have not been performed. OBJECTIVE: We compare the performance characteristics of three PF4-enhanced platelet activation assays, the PF4/heparin-SRA (PF4/hep-SRA), the PF4-SRA, and the P-selectin expression assay (PEA), at a single reference laboratory. METHODS: Serum samples from two cohorts of patients were used. The referral cohort (n = 84) included samples that had previously undergone routine diagnostic testing for HIT and tested positive or negative using the SRA. The clinical cohort (n = 101) consisted of samples from patients with clinically confirmed HIT whose serum contained platelet-activating antibodies. We simultaneously tested all samples in PF4-enhanced SRA-based assays (PF4/hep-SRA, PF4-SRA) and the flow cytometry-based PEA. RESULTS: In the referral cohort, the three PF4-enhanced assays identified all samples that were previously determined to be positive in the SRA. However, specificity of the PF4/hep-SRA was 96.6%, the PF4-SRA was 84.7%, and the PEA was 67.8%. In the clinical cohort of samples, all SRA-based assays displayed high performance characteristics (>92.1% sensitivity, >98.4% specificity). Sensitivity and specificity of the PEA was the lowest, 65.8% and 63.5%, respectively; but improved to 92.1% and 96.8% using preselected platelet donors. CONCLUSIONS: All PF4-enhanced assays demonstrated good performance characteristics when platelet donors were preselected. Further comparisons across multiple laboratories should be conducted for consensus on optimal HIT diagnostic testing.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Rubino JG, Arnold DM, Warkentin TE, et al. A comparative study of platelet factor 4-enhanced platelet activation assays for the diagnosis of heparin-induced thrombocytopenia. J Thromb Haemost. 2021. PMID: 33387395. doi:10.1111/jth.15233

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。